



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	292182	Zinc Citrate
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Bio-Practica Pty Ltd	
<b>Postal Address</b>	651 Portrush Road, GLEN OSMOND, SA, 5064 Australia	
<b>ARTG Start Date</b>	28/07/2017	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Zinc Citrate

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	28/07/2022
---------------------	-------------------------	-----------------------	------------

### Permitted Indications

Antioxidant/Reduce free radicals formed in the body  
Maintain/support healthy eye function  
Maintain/support eye health  
Maintain/support healthy eyesight/vision  
Maintain/support healthy growth and development  
Maintain/support general health and wellbeing  
Maintain/support hair health  
Maintain/support nail health/strength/thickness  
Maintain/support connective tissue health  
Maintain/support bone health  
Maintain/support digestion/assimilation of nutrients  
Maintain/support immune system health  
Maintain/support healthy immune system function  
Aid/assist/helps glucose/sugar/carbohydrate metabolism  
Aid/assist/helps protein synthesis in the body  
Helps prevent dietary (state vitamin/mineral/nutrient) deficiency  
Maintain/support nervous system health  
Maintain/support nervous system function  
Maintain/support nervous system function  
Maintain/support healthy reproductive hormones  
Helps maintain/support testosterone formation/synthesis  
Maintain/support sperm production  
Maintain/support skin health  
Maintain/support skin integrity/structure  
Maintain/support skin regeneration  
Maintain/support wound healing  
Maintain/support skin repair/healing/regeneration

Public Summary



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

**Indication Requirements**

Product presentation must not imply or refer to serious immunological diseases.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to vision correction, faults or serious eye disease e.g. macular degeneration.

Product presentation must not imply or refer to infertility.

Product presentation must not imply or refer to hormone imbalances.

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

WARNING: May be dangerous if taken in large amounts or for a long period. OR WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).

**Additional Product information**

**Pack Size/Poison information**

**Pack Size** **Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form** Capsule, hard

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

**zinc citrate dihydrate** **155.8 mg**

Equivalent: zinc 50 mg

**Other Ingredients (Excipients)**

**Gelatin**

**magnesium stearate**

**microcrystalline cellulose**

**purified water**

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.